Heart and neoplasms;Corazon y neoplasias

Revista Espanola de Cardiologia

Volumn 51, Issue 4, 1998, Pages 314-331

  Calzas, Julia ^a   Lianes, Pilar ^a,b   Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b NONE   (Spain)

Author keywords

Adriamycin; Cardiotoxicity; Neoplasms

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ESORUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALOPECIA; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER; CANCER RADIOTHERAPY; CARDIOTOXICITY; DRUG SAFETY; HEART METASTASIS; HEART PROTECTION; HUMAN; MUCOSA INFLAMMATION; PERICARDITIS; RADIATION INJURY; REVIEW; SUPERIOR CAVA VEIN SYNDROME; VOMITING; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HEART; HEART DISEASE; HEART TUMOR; MALE; METASTASIS; NEOPLASM; RADIOTHERAPY; RISK FACTOR;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHILD; DOXORUBICIN; FEMALE; HEART; HEART DISEASES; HEART NEOPLASMS; HUMANS; MALE; NEOPLASMS; RADIOTHERAPY; RISK FACTORS; SUPERIOR VENA CAVA SYNDROME;

EID: 0032044253     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(98)74751-7     Document Type: Review

References (251)

1. a ed.). Filadelfia: Saunders, 1997.
2. Kapoor AS. Cancer of the heart. Nueva York: Springer-Verlag, 1986.
3. Smith C. Tumors of the heart. Arch Pathol Lab Med 1986; 110; 5: 371-374.
4. Fyke FE, Seqard JB, Edwards WD et al. Primary cardiac tumors: experience with 30 consecutive patients since the introduction of two dimensional echocardiography. J Am Coll Cardiol 1985; 5: 1.465.
5. Verkkala K, Kupari M, Maamies T et al. Primary cardiac tumors-operative treatment of 20 patients. Thorac Cardiovasc Surg 1989; 37: 361.
6. Bulkley BH, Hutchins GM. Atrial myxomas: a fifty year review. Am Heart J 1979; 97: 639-643.
7. Schoen FJ, Berger BM, Guerina NG. Cardiac effects of noncardiac neoplasms. Cardiol Clin 1984; 2: 657-670.
8. Kutalek SP, Panidis IP, Kotler MN, Mintz GS, Carver J, Ross JJ. Metastatic tumors of the heart detected by two dimensional echocardiography. Am Heart J 1985; 109: 343-349.
9. Kralstein J, Frishman W. Malignant pericardial disease: diagnosis and treatment. Am Heart J 1987; 113: 785-790.
10. a ed.). Filadelfia: Lippincott-Raven, 1997: 2.586-2.598.
11. Hancock EW. Pericardial disease in patients with neoplasm. En: Reddy RS, Leon DF, Shaver JA, editores. Pericardial disease. Nueva York: Raven Press, 1981; 327.
12. Mukai K, Shinkai T, Tominagak, Shimasato Y. The incidence of secondary tumors of the heart and pericardium: a ten-year study. Jpn J Clin Oncol 1988; 18: 195-201.
13. Chan HS, Sonley MJ, Moes CA, Daneman A, Smith CR, Martin DJ. Primary and secondary tumors of childhood involving the heart, pericardium and great vessels. Cancer 1985; 56: 825-836.
14. Wilding G, Green HL, Longo DL, Urba WJ. Tumors of the heart and pericardium. Cancer Treat Rev 1988; 15: 165-181.
15. López JM, Delgado JL, Tovar E, González AG. Massive pericardial effusion produced by extracardiac malignant neoplasms. Arch Intern Med 1983; 143: 1.815-1.816.
16. Skhvatsabaju LV. Secondary malignant lesions of the heart and pericardium in neoplasic disease. Oncology 1986; 43: 103-106.
17. Shinkai T, Tominaga K, Saijo N, Eguchi K, Shimizu E, Shibuya M et al. The incidence of cardiac metastases in primary lung cancer and the management of malignant pericardial effusion. Jpn J Clin Oncol 1982; 12: 23-32.
18. Buck M, Ingle JN, Guilani ER, Gordon JR, Therneau TM. Pericardial effusion in women with breast cancer. Cancer 1987; 60: 263-269.
19. MarKiewicz W, Glatstein E, London EJ, Popp RL. Echocardiograhic detection of pericardial effusion and pericardial thickening in malignant lymphoma. Radiology 1977; 123: 161-164.
20. Posner MR, Cohen GI, Skarin AT. Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis. Am J Med 1981; 71: 407-413.
21. Engberding R, Schulze-Waltrup N, Grosse-Heitmayer W, Stoll V. Transthoracic and transesophageal 2-D echocardiography in the diagnosis of peri and paracardiac tumors. Dtsch Med Wochenschr 1987; 112: 49-52.
22. Brown JJ, Barakos JA, Higgins CB. Magnetic resonance imaging of cardiac and paracardiac masses. J Thorac Imagin 1989; 4: 58-64.
23. Yazdi HM, Hajdu SI, Melamed MR. Cytopathology of pericardial effusions. Acta Cytol J 1980; 24: 401-412.
24. Reyes CV, Strinden C, Banerji M. The role of cytology in neoplastic tamponade. Acta Cytol 1982; 26: 299-302.
25. Ramarkrishnan S, Marshall AJ, Pickard JG, Tyrrell CJ. Pericardiocentesis and systemic cytotoxic chemotherapy in the management of cardiac tamponade secondary to disseminated breast carcinoma. Br Heart J 1988; 60: 162-164.
26. Leung WH, Tai YT, Lau CP, Wong CK, Cheng CH, Chan TK. Cardiac tamponade complicating leukaemia: immediate chemotherapy or pericardiocentesis? Postgrad Med J 1989; 65: 773-775.
27. Press OW, Liviagston R. Management of malignant pericardial effusion and tamponade. JAMA 1987; 257: 1.088-1.092.
28. Markman M, Howell SB. Intrapericardial instillation of cisplatin in a patient with a large malignant effusion. Cancer Drug Deliv 1985; 2: 49-50.
29. Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D, Murphy K. Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 1987; 60: 1.161-1.166.
30. Maher ER, Buckman R. Intrapericardial installation of bleomycin in malignant pericardial effusion. Am Heart J 1986; 111: 613-614.
31. Primrose WR, Clee MD, Johnston RN. Malignant pericardial effusion managed with vinblastine. Clin Oncol 1983; 9: 67-70.
32. Florentino MV, Daniele O, Morandi P, Aversa SM, Ghiotto C, Paccagnella A et al. Intrapericardial instillation of platin in malignant pericardial effusion. Cancer 1988; 62: 1.904-1.906.
33. Cham WC, Freiman AH, Carstens PHB et al. Radiation therapy of cardiac and pericardial metastases. Radiology 1975; 114: 701-703.
34. Hawkins JW, Vacek JL. What constitutes definitive therapy of malignant pericardial effusion? Medical versus surgical treatment. Am Heart J 1989; 118: 428-432.
35. Gregory JR, McMurtrey MJ, Mountain CF. A surgical approach to the treatment of pericardial effusion in cancer patients. Am J Clin Oncol 1985; 8: 319-323.
36. Little AG, Kremser PC, Wade JL, Levett JM, DeMeester TR, Skinner DB. Operation for diagnosis and treatment of pericardial effusions. Surgery 1984; 96: 738-744.
37. Mills SA, Julian S, Holliday RH, Vinten-Johansen J, Case LD, Hudspeth AS et al. Subxiphoid pericardial window for pericardial effusive disease. J Cardiovasc Surg 1989; 30: 768-773.
38. Campbell PT, Van Tright P, Wall TC, Kenney RT, O'Connor CM, Sheikh KH et al. Subxiphoid pericardiotomy in the diagnosis and management of large pericardial effusions associated with malignancy. Chest 1992; 101: 938-943.
39. Ghosh SC, Larrieu A, Ablaza S et al. Clinical experience with subxyphoid pericardial decompression. Int Surg 1985; 70: 5-9.
40. Reitknecht F, Regal AM, Antkowiak JG, Takita H. Management of cardiac tamponade in patients with malignancy. J Surg Oncol 1985; 30: 19-22.
41. Osuch JR, Khandekar JN, Fry WA. Emergency subxyphoid pericardial decompression for malignant pericardial effusion. Am Surg 1985; 51: 298-300.
42. Alcan KE, Zabetakis PM, Marino ND. Management of acute cardiac tamponade by subxiphoid pericardiotomy. JAMA 1982; 247: 1.143-1.145.
43. Hankins JR, Satterfield JR, Aisner J, Wiernik PH, McLaughlin JS. Pericardial window for malignant pericardial effusion. Ann Thorac Surg 1980; 30: 465-471.
44. Scbraufnagel DE, Hill R, Leech JA, Pare JAP. Superior vena caval obstruction: is it an emergency? Am J Med 1981; 70: 1.169-1.172.
45. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 1987; 13: 531-539.
46. Parish JM, Marschke RF, Dines DE, Lee RE. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 1981; 56: 407-410.
47. Bell DR, Woods RL, Levi JA. Superior vena caval obstruction: a 10-year experience. Med J Aust 1986; 145: 566-568.
48. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome: the myth-the facts. Am Rev Respir Dis 1990; 141: 1.114-1.118.
49. a ed.). Filadelfia: Lippincott-Raven, 1997; 2.469-2476.
50. Chen JC, Bongard F, Klein SR. A contemporary perspective on superior vena cava syndrome. Am J Surg 1990; 160: 207-211.
51. Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology and treatment Curr Probl Cancer 1986; 10: 441-484.
52. Dombernowsky P, Hansen HH. Combination chemotherapy in the management of superior vena caval obstruction in small cell anaplastic of the lung. Acta Med Scand 1978; 204: 513-516.
53. Sculier JP, Evans WK, Feld R, DeBoer G, Payne DG, Shepherd FA et al. Superior vena caval obstruction in small cell lung cancer. Cancer 1986; 57: 847-851.
54. Spiro SG, Shah S, Harper PG, Tobias JS, Geddes DM, Souhami RL. Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small cell carcinoma of the bronchus. Thorax 1983; 38: 501-505.
55. Urban T, Lebeau B, Chastang C, Leclerc P, Botto MJ, Sauvaget J. Superior vena cava syndrome in small cell lung cancer. Arch Intern Med 1993; 153: 384-387.
56. Wurschmidt F, Bunemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. Int J Radiol Oncol Biol Phys 1995; 33: 77-82.
57. Perez-Soler R, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT et al. Clinical features and results of managemente of superior vena cava syndrome secondary to lymphoma. J Clin Oncol 1984; 2: 260-266.
58. Yellin A, Mandel M, Rechavi G. Neuman Y, Ramot B, Lieberman Y. Superior vena cava syndrome associated with lymphoma. Am J Dis Child 1992; 146: 1.060-1.063.
59. Bertrand M, Presant CA, Klein L, Scott E. Yatrogenic superior vena cava syndrome: a new entity. Cancer 1984; 54: 376-378.
60. Ingram L, Rivera GK, Shapiro DN. Superior vena cava syndrome associated with childhood malignancy: analysis of 24 cases. Med Pediatr Oncol 1990; 18: 476-481.
61. Sculier JP, Feld R. Superior vena cava obstruction: system-recommendation for management. Cancer Treat Rev 1985; 12: 209-218.
62. Perez CA, Presant CA, Van Amburg AL III. Management of superior vena cava syndrome. Semin Oncol 1978; 5: 123-134.
63. Rodriguez CI, Njo KH, Karim ABMF. Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung Cancer 1993; 10: 221-222.
64. Painter TD, Karpf M. Superior vena cava syndrome: diagnostic procedures. Am J Med Sci 1983; 285: 2-6.
65. Jahangiri M, Taggart DP, Goldstraw P. The role of mediastinoscopy in superior vena caval obstruction. Cancer 1993; 71: 3.006-3.008.
66. Cosmo L, Haponik EF, Darlak JJ, Summer WR. Neoplastic superior vena caval obstruction: diagnosis with percutaneous needle aspiration. Am J Med Sci 1987; 293: 99-102.
67. Walpole HT Jr, Lovett KE, Chuang VP, West R, Clements SD Jr. Superior vena cava syndrome treated by percutaneous transluminal balloon angioplasty. Am Heart J 1988; 115: 1.303-1.306.
68. Hennequin LM, Fade O, Fays JG et al. Superior vena cava stent placement-results with the Wallsstent endoprosthesis. Radiology 1995; 196: 353-357.
69. Gaines PA, Belli AM, Anderson PB, McBride K, Hemingway AP. Superior vena caval obstruction managed by the Gianturco Z stent. Clin Radiol 1994; 49: 202-205.
70. Oudkerk M, Heystraten FM, Stoter G. Stenting in malignant vena caval obstruction. Cancer 1993; 71: 142-146.
71. Gray BH, Olin JW, Grador RA, Young JR, Bartholomew JR, Ruschpaupt WF. Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 1991; 99: 54-59.
72. Comerota AJ. Safety and efficacy of thrombolytic therapy for superior vena caval syndrome. Chest 1991; 99: 3-4.
73. Marmont AM, Damasio E, Rossi F. Cardiac toxicity of daunorubicin. Lancet 1969; 1: 837-838.
74. Lefrak EA, Pitha J, Rosenheim S et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-314.
75. Halazun JF, Wagner HR, Gaeta JF et al. Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia. Cancer 1974; 33: 545-554.
76. Praga C, Beretta G, Vigo PL et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-834.
77. Steinberg JS, Cohen AJ et al. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1.213-1.218.
78. Bristow MR, Thompson PD, Martin RP et al. Early anthracycline cardiotoxicity. Am J Med 1978; 65: 823-832.
79. Von Hoff DD, Layard M, Basa P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 701-717.
80. Von Hoff DD, Rozencweig M, Layard M et al. Daunomycin-induced cardiotoxicity in children and adults. Am J Med 1977; 62: 200-208.
81. Gottlieb SL, Edmiston WA, Haywood LJ. Late doxorubicin cardiotoxicity. Chest 1980; 78: 880-882.
82. Sperber AD, Canter AA, Biron H, Keynan A. Selective right ventricular dysfuntion following doxorubicin therapy. Isr J Med Sci 1987; 23: 896-899.
83. Cohen M, Kronzon I, Lebowitz A. Reversible doxorubicin-induced congestive heart failure. Arch Intern Med 1982; 142: 1.570-1.571.
84. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Ann Intern Med 1987; 106: 814-816.
85. Yeung ST, Yoong C, Spink J, Galbraith A, Smith PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991; 337: 816-818.
86. Moreb JS, Oblon AJ. Outcome of clinical congestive heart failure induced by antracycline chemotherapy. Cancer 1992; 70: 2.637-2.641.
87. Shaddy RE, Olsen SI, Bristow MR, Taylor DO, Bullock EA, Tani LY et al. Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J 1995; 129: 197-199.
88. Arico M, Nespoli L, Pedroni E, Bonetti F, Vigano M, Burgio GR. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N Engl J Med 1988; 654: 1.353-1.354.
89. Arico M, Pedroni E, Nespoli K et al. Long term survival after heart transplantation for doxorubicin induced cardiomyopathy. Arch Dis Child 1991; 66: 985-986.
90. Jenney ME, Jones PH. Long term survival after heart transplantation for doxorubicin induced cardiomyopathy. Arch Dis Child 1992; 67: 153.
91. Lamonte CS, Yeh SD, Straus DJ. Long term follow up of cardiac function in patients with Hodgkins disease treated with mediastinal irradiation and combination chemotherapy including doxorubicin. Cancer Treat Rep 1986; 70: 439-444.
92. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiotoxicity 4-20 years after completing anthracycline therapy. JAMA 1991; 266: 1.672-1.677.
93. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24: 352-361.
94. Goorin AM, Chauvenet AR, Pere-Atayde AR et al. Initial congestive heart failure, six to ten years after doxorubictn chemotherapy for childhood cancer. J Pediatr 1990; 116: 144-147.
95. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin in childhood lymphoblastic leukemia. N Engl J Med 1991; 324: 808-815.
96. Hausdorf G, Morf G, Beron G et al. Long term doxorubicin cardiotoxicity in childhood-non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 1988; 60: 309-315.
97. Sorensen K, Levitt G, Sebag-Montefiore D, Bull C, Sullivan I. Cardiac funtion in Wilms tumor survivors. J Clin Oncol 1995; 13: 1.546-1.556.
98. Leandro J, Dyck J, Poppe D, Shore R, Airhart C, Greenberg M et al. Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 1994; 74: 1.152-1.156.
99. Pihkala J, Happonen JM, Virtanen K et al. Cardiopulmonary evaluation of exercise tolerance after chest irradiation and anticancer chemotherapy in children and adolescents. Pediatrics 1995; 95: 722-726.
100. Jakacki RI, Larsen RL et al. Cardiac function following cardiotoxic therapy during childhood: assessing the damage. En: Bricker JT, Green DM, D'Angio GJ, editores. Cardiac toxicity after treatment for childhood cancer. Nueva York: Wiley-Liss, 1993; 87-99.
101. Stoddard MF, Seeger J, Liddell EN, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992; 20: 62-69.
102. Steinherz LJ, Steinherz PG, Heller G. Anthracycline-related cardiac damage. En: Bricker JT, Green DM, D'Angio GJ, editores. Cardiac toxicity after treatment for childhood cancer. Nueva York: Wiley-Liss, 1993; 63-72.
103. Hausdorf G. Late efects of anthacycline therapy in childhood: evaluation and current therapy. En: Bricker JT, Green DM, D'Angio GJ, editores. Cardiac toxicity after treatment for childhood cancer. Nueva York: Wiley-Liss, 1993; 73-80.
104. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1.738-1.743.
105. Silber JH, Jakacki RI, Larsen RL, Goldwein JW, Barber G. Increased risk of cardiac disfunction after anthracyclines in girls. Med Pediatr Oncol 1993; 21: 477-479.
106. Minow RA, Benjamin RS, Lee ET et al. QRS voltage change with adriamicin administration. Cancer Treat Rep 1978; 62: 931-934.
107. Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep 1978; 62: 1.381-1.385.
108. Obama M, Cangir A, Van Eys J. Nutritional status and anthracycline cardiotoxicity in children. South Med J 1983; 76: 577.
109. Merrill J, Greco FA, Zimbler H et al. Adriamycin and radiation: synergistic cardiotoxicity. Ann Intern Med 1975; 82: 122-125.
110. Ace A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529-542.
111. Bristow MR, Mason JW, Billinghan ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978; 88: 168-175.
112. Billingham ME, Mason JW, Bristow MR et al. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978; 62: 865-869.
113. Billingham ME, Masek MA. The pathology of anthracycline cardiotoxicity in children, adolescents, and adults. En: Bricker JT, Green DM, D'Angio GJ, editores. Cardiac toxicity after treatment for childhood cancer. Nueva York: Wiley-Liss. 1993: 17.
114. Ito H, Miller SC, Billingham ME, Akimoto H, Toni SV, Wade R et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 1990; 87: 4.275-4.279.
115. Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxiciyty. Biochem Biophys Res Comm 1993; 195: 945-951.
116. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460-472.
117. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart implications for cardiotoxicity. Cancer Res 1988; 48: 4.766-4.769.
118. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 2.829-2.835.
119. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995; 91: 10-15.
120. Singal PK, Siveski-Iliskovic, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J Mol Cell Cardiol 1995; 27: 1.055-1.063.
121. Jackon JA, Reeves JP, Muntz KH et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984; 117: 140.
122. Kusuoka H, Futaki S, Koretsuae Y, Kitabatake A, Suga H, Kamada T et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol 1991; 18: 437-444.
123. Holmberg SR, Willians AJ. Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res 1990; 67: 272-283.
124. Wang YX, Korth M. Effects of doxorubicio on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res 1995; 76: 645-653.
125. Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ, Fleischer S et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 1993; 91: 1.697-1.705.
126. Shenasa H, Calderone A, Vermeulen M et al. Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the falling myocardium. Cardiovasc Res 1990; 24: 591-604.
127. Wakasugi S, Wada A, Hasegawa Y, Nakano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med 1992; 33: 208-214.
128. Valdes Olmos RA, Ten Bokkel Huinink WW, Ten Hoeve RF, Van Tinteren H, Bruning PF, Van Vlies B et al. Assessment of anthracycline-related myocardial adrenergic derangement by iodo 123 metaiolobenzylguanidine scintigraphy. Eur J Cancer 1995; 31A: 26-31.
129. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Billingham ME et al. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 1983; 5: 913-919.
130. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-566.
131. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1.479-1.486.
132. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expresion and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1.487-1.493.
133. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular eyection fraction: a report from the studies of left ventricular dysfunction. J Am Cell Cardiol 1996; 27: 1.201-1.206.
134. Cappelli V, Moggio R, Monti E, Paracchini L, Piccinini F, Reggiani C. Reduction of myofibrillar ATPase activity and isomyosin shift in delayed doxorubicin cardiotoxicity. J Mol Cell Cardiol 1989; 21: 93-501.
135. Cusack BJ, Mushlin PS et al. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol? Toxicol Appl Pharmacol 1993; 118: 177-185.
136. Steinherz LJ, Graham T, Hurwitz R et al. Guidelines for cardiac monitoring of children during and after anthrcycline therapy-report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-949.
137. Iacuone J, Steinherz LJ, Ablin AR. Modifications for toxicity. En: Ablin AR, editor. Supportive care of children with cancer: current therapy and guidelines from the Childrens Cancer Group. Baltimore: Johns Hopkins University Press, 1993; 37-42.
138. Sandor GG, Puterman M, Rogers P, Chan KW, Pritchard S, Popov R. Early prediction of anthracycline cardiomyopathy usin standard M-mode and digitized echocardiography. Am J Pediatr Hematol Oncol 1992; 14: 151-157.
139. BuLock FA, Martin RP, Oakhill A, Mott MG. Early identification of patients with significant anthracycline cardiotoxicity: potential for prevention of late sequelae. Med Pediatr Oncol SIOP XXVI Meeting 1994; 23: A187.
140. Schwartz RG, McKenzie WB, Alexander S et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: a seven year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1.109-1.118.
141. Palmen ST, Bonow RO, Myers CE et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiopraphy. Am J Cardiol 1986; 58: 607-613.
142. McKillop JH, Bristow MR, Goris ML et al. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983; 106: 1.048-1.056.
143. Ewer MS, Carrasco CH, Mackay B, Ali MK, Benjamin RS. Cardiac biopsy procedures at a cancer center. Proc Annu Meet Am Soc Clin Oncol 1991; 10: A1.189.
144. Mackay B, Ewer MS, Carrasco CH, Benjamin RS. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 1994; 18: 203-211.
145. Dreyer Z, Guidry G, Mahoney D et al. Tantalum-178 first pass radionuclide imaging (Ta-RNA) sensitive early detection of cardiac dysfunction(CD) in anthracycline (ANTH) treated pediatric patients. Proc Annu Meet Am Soc Cin Oncol 1994; 13: A1.499.
146. Estorch M, Carrió I, Berna L et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990; 31: 1.965-1.969.
147. Jain D, Zaret BL. Antiomyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? J Nucl Med 1990; 31: 1.970-1.974.
148. Carrió I, López-Pousa A, Estorch M, Duncker D, Berna L, Torres G et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 1993; 34: 1.503-1.507.
149. Estorch M, Carrió I, Martínez-Duncker D, Berna L, Torres-G, Alonso C et al. Myocyte cell damage after administration of doxorubicin or mitoxantrone in antibody studies. J Clin Oncol 1993; 11: 1.264-1.268.
150. Fink FM, Genger N, Fink C, Falk M, Mair J, Maurer-Dengg K. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 225: 185-189.
151. Bauch M, Ester A, Kimura B, Victoria BE, Kedar A, Phillips MI. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992; 69: 1.492-1.497.
152. Sonneveeld P. Effect of alpha-tocopherol on the cardiotoxiciry of adriamycin in the rat. Cancer Treat Rep 1978; 62: 1.033-1.036.
153. Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamoto M et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991; 54 (Supl): 1.298-1.301.
154. Villani F, Galimberti M, Monti E et al. Effect of glutathione and N-acetylcysteine on in vitro and in vivo cardiac toxicity of doxorubicin. Free Radic Res Commun 1990; 11: 145-151.
155. Kraft J, Grille W, Appelt M et al. Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. Hamatol Bluttransfus 1990; 33: 566-570.
156. Akimoto H, Bruno NA, Slate DL, Billingham ME, Torti SV, Torti FM et al. Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes. Cancer Res 1993; 53: 4.658-4.664.
157. Milei J, Marantz A, Ale J, Vazquez A, Buceta JE. Prevention of adriamycin-induce cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv 1987; 4: 129-136.
158. Milei J, Vazquez A, Boveris A et al. The role of prenylamine in the prevention of adriamycin-induced cardiotoxicity: a review of experimental and clinical findings. J Int Med Res 1988; 16: 19-30.
159. Bartoli KF, Decorti G, Candussio L et al. Effect of ketotifen on adriamycin toxicity: role of histamine. Cancer Lett 1988; 39: 145-152.
160. Northfelt D et al. Pharmacokinetics, tumor localization and safety of caelyx in AIDS patients with Kaposi sarcoma. Proc Am Soc Clin Oncol 1993; 12: A51.
161. Northfelt DW, Dezube BJ, Thommes JA. Efficacy of pegylated-liposomal doxurubicin in the treatment of AIDS-related Kaposi's sarcoma ofter failure of standard chemoterapy. J Clin Oncol 1997; 15: 653-659.
162. Gabizon A, Uzliely B, Lotem M. Doxil in patients with pretreated metastatic breast cancer: a dose-shedule finding study with pharmacokinetics [resumen]. Proc Am Soc Clin Oncol 1997; 16: 147A.
163. Berry G, Billinghan M, Alderman E et al. Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared a matched control group of cancer patients given doxorubicin [resumen]. Proc Am Soc Clin Oncol 1996; 15: 303A.
164. Ranson M, O'Bymeki Carmichael J et al. Phase II dose-finding trial of dosil in the treatment of advanced breast cancer. Proc Am Soc Clin Oncol 1996; 15: A161.
165. Muggia F, Hainsworth S et al. Liposomal adryamicin (doxil) is active against refractary ovarian cancer. Proc Am Soc Clin Oncol 1996; 15: A781.
166. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1.777-1.785.
167. Alexander J. Dexrazoxane (Zinecard) reduces the incidence and severity of cardiotoxicity associated with doxorubicin. J Cardiovasc Diag Proc 1996; 13: A49.
168. Wexler LH, Andrich MP, Venzon D et al. Dexrazoxane protects against doxorubicin-tnduced chronic cardiotoxicity. Proc Am Soc Clin Oncol 1996; 14: A362.
169. Swain SM, Whaley FS, Gerber CM, Welsberg S, York M, Spicer D et al. Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1.318-1.332.
170. Swain SM, Whaley FS, Gerber CM, Ewer MS, Bianchine Jr, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1.333-1.340.
171. Speyer JL, Green MD, Kramer E et al. Protective effect of ICRF-187 against doxorubicin-induced cardiac toxicity in women with breast cancer. N Engl J Med 1988; 319: 745-752.
172. Ventunni M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3.112-3.120.
173. Chelebowski RT et al. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 1980; 64: 47-49.
174. Valdivieso M, Burgess MA, Ewer MS, Mackay B, Wallace S, Benjamin RS. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancen a prospective, randomized study. J Clin Oncol 1984; 2: 207-214.
175. Benjamin RS et al. Continuous-infusion adriamycin. En: Rosenthal CJ, Rotman M, editores. Clinical applications of continous infusion chemotherapy and concomitant radiation therapy. Nueva York: Plenum Press, 1986.
176. Hortobagy GN, Frye D, Buzdar AV, Ewer MS, Fraschini G et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastasic breast carcinoma. Cancer 1989; 63: 37-45.
177. Chawla SP. Decreased cardiotoxicity of 96 hour continuous infusion adramycin compared with epirubicin. Proc Am Soc Clin Oncol 1986; 5: A44.
178. Casper ES, Gaynor JJ, Hajdu SI et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68: 1.221-1.229.
179. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6 hour infusion regimen. Cancer 1990; 65: 870-873.
180. Ewer M, Benjamin R. Prevention of cardiac damage due to adriamycin-modification of method of administration. En: Bricker JT, Green DM, D'Angio GJ, editores. Cardiac toxicity after treatment for childhood cancer. Nueva York: Wiley-Liss, 1993; 109-120.
181. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and antitumour efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-882.
182. Torti FM, Bristow MR, Howes AE et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule-assessment by endomyocardial biopsy. Ann Intern Med 1983; 99: 745-749.
183. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197-228.
184. Jain KK, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818-826.
185. Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F et al. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 1986; 70: 261-266.
186. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin. J Clin Oncoll 1988; 6: 679-688.
187. Italian Multicentre Breast Study with Epirubicin Group. Phase III randomized study of fluouracil. doxorubicin and cyclophosphamide versus fluouracil, epirubicin and cyclophosphamide in advanced breast cancer: an italian multicenter study. J Clin Oncol 1988; 6: 976-982.
188. Shipp NG, Dorr RT. Biochemical effects and toxicity of mitoxantrone in cultured heart cells. Adv Exp Med Biol 1991; 283: 8.215.
189. Colomer R. Novantrone a dosis altas en linfomas. Rev Cancer 1996; 10
190. Saletan S. Mitoxantrone-an active, new antitumor agent with an improved therapeutic index. Cancer Treat Rev 1987; 14: 297-303.
191. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitroxantrone-an overview of safety and toxicity. Invest N Drugs 1985; 3: 123-132.
192. Janmohammed R, Milligan DW. Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines. Br J Haematol 1989; 71: 292-293.
193. Onetton, Dougan M et al. Safety profile. En: McGuire WP, Rowinsky EK, editores. Paclitaxel in cancer treatment. Nueva York: Marcel Dekker, 1995; 121-130.
194. Brouty-Boye D, Kolonias D, Lampidis TJ. Antiproliferative activity of taxol on human tumor and normal breast cells versus effects on cardiac cells. Int J Cancer 1995; 60: 571-575.
195. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9: 1.704-1.712.
196. Arbuck SG, Adams J, Strauss H et al. A reassessment of cardiac toxicity associated with taxol. Second Natl Cancer Inst Workshop on taxol. Alexansdria VA: National Cancer Institute, 1992.
197. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicity encountered with paclitaxel. Semin Oncol 1993; 20 (Supl 3): 1-15.
198. Gardner SF, Lazarus HM, Bednarczyk EM, Creger RJ, Miraldi FD, Leisure G et al. High-dose cyclophosphamide induced myocardial damage during BMT: assessment by position emission tomography. Bone Marrow Transpl 1993; 12: 139-144.
199. Gottdiener JS, Applebaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
200. Steinherz LJ, Steinherz PG. Cyclophosphamide cardiotoxicity. Cancer Bull 1985; 37: 231-234.
201. Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transpl 1990; 5: 91-94.
202. Braverman AC et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosin regimens. J Clin Oncol 1991; 9: 1.215-1.223.
203. Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Goller V, Clausen M et al. Cardiac toxicity of bone marrow transplantation: preventive value of cardiologic evaluation before transplant. J Clin Oncol 1994; 12: 998-1.004.
204. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989; 24: 395-396.
205. Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G et al. High-dose ifosfamide is associated with severe reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-36.
206. Lomeo AM, Avolio C, Iacobellis G, Manzione L. 5-Fluorouracil cardiotoxicity. Eur J Gynaec Oncol 1990; 3: 237-241.
207. De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1.795-1.801.
208. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 1993; 33: 1.060-1.070.
209. Freeman NJ, Costanza ME. 5-fluorouracil-associated cardiotoxicity. Cancer 1988; 61: 36-45.
210. Weidmann B, Jansen W et al. 5-fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. Am J Cardiol 1995; 75: 194-195.
211. Misset B, Escudier B, Leclercq, Rivara D, Rougier P, Nitenberg G. Acute myocardiotoxicity during 5-fluorouracil therapy. Intens Care Med 1990; 16: 210-211.
212. Burger AJ, Mannino S. 5-fluorouracil-mduced coronary vasospasm. Am Heart J 1987; 114: 433-436.
213. Jeremic B, Jevremovic S et al. Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. J Chemother 1990; 2: 264-267.
214. Menard O, Martinet Y, Lamay P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991; 9: 192-193.
215. Fassio T, Canobbio L, Gasparini G, Villani F. Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination. Oncology 1986; 43: 219-220.
216. Doll DC, List AF, Greco A, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 1986; 105: 48-51.
217. Burkhardt A et al. Vascular lesion following perfusion with bleomycin-electron-microscopic observations. Virchows Arch Pathol Anat 1976; 372: 227.
218. White DA, White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer 1987; 59: 1.582-1.585.
219. Lindpaintner K, Lindpaintner LS, Wentworth M et al. Acute myocardial necrosis during administration of amsacrine. Cancer 1986; 57: 1.284-1.286.
220. Arlin ZA, Metha R, Feldman EJ, Sullivan P, Pucillo A. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer Chemother Pharmacol 1987; 19: 163-164.
221. Hirvonen HE, Salmi TT, Heinonen E, Anntila KJ, Valimaki IA. Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 1989; 64: 801-805.
222. Cargill RI, Boyter AC, Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir Med 1994; 88: 709-710.
223. Zeymer U, Neuhaus KL. Infarct-rypical changes in the electrocardiogram following chemotherapy with vinblastine. Dtsch Med Wochenschr 1989; 114: 589-592.
224. Schecter JP, Jones SE. Myocardial infarction in a 27 year old woman: possible complication of treatment with VP16, mediastinal irradiation or both. Cancer Chemother Rep 1975; 59: 887-888.
225. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991; 99: 557-561.
226. Zbinden G. Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. Toxicol Lett 1990; 50: 25-35.
227. Kruit WH, Punt KJ, Goey SH, De Mulder PH, Van Hoogenhuyze DC, Henzen-Logmans SC et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. Cancer 1994; 74: 2.850-2.856.
228. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. Br Med J 1990; 300: 1.174-1.175.
229. Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ. Myocardial toxic effects during recombinant interleukin-2-therapy. J Natl Cancer Iast 1989; 81: 59-63.
230. Schechter D, Nagler A, Ackerstein A, Nassar H, Admon D, Naparstek et al. Recombinant Interleukin-2 and Interferon Alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation. Cardiology 1992; 80: 168-171.
231. White RL Jr, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74: 3.212-3.222.
232. Watanabe H, Watanabe H, Hasegawa A, Shinozaki T, Arita S, Chigira M. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995; 35: 278-282.
233. Cameron HA et al. Cardiac arrest after treatment with intravenous domperidone. Br Med J 1985; 290: 160-161.
234. a ed.). Lippincott Company, 1992.
235. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 1991; 33: 299-312.
236. Benoff LJ, Schweitzer P. Radiation therapy-induced cardiac injury. Am Heart J 1995; 129: 1.193-1.196.
237. Stewart JR, Fajardo LF, Cohn KE. Experimental radiation induced-heart disease in rabitts. Radiology 1968; 91: 814-817.
238. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin disease in children and adolescents. J Clin Oncol 1993; 1: 1.208-1.215.
239. Corn BW, Trock BJ, Goodman RL. Irradiation-related ischemic heart disease. J Clin Oncol 1990; 8: 741-750.
240. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkins disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990; 18: 275-281.
241. Gottdeiner JS, Katin MJ, Borer JS et al. Late cardiac effects of therapeutic mediastinal irradiation: assessment by echocardiography and radionuclide angiography. N Engl J Med 1983; 308: 569-572.
242. Loyer EM, Delpassand ES. Radiation induced heart diseaseimaging features. Semin Roentgenol 1993; 28: 321-332.
243. Savage DE, Constine LS, Schwartz RG, Rubin P. Radiation effects of left ventricular function and myocardial perfusion in long-term survivors of Hodgkin disease. Int J Radiat Oncol Biol Phys 1990; 19: 721-727.
244. Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin disease. Radiother Oncol 1994; 30: 43-54.
245. Strender LE, Lmdahl J, Larsson LE. Incidence of heart disease and functional significance of change in the electrocardiogram 10 years after radiotherapy for breast cancer. Cancer 1986; 57: 929-934.
246. Orzan F, Brusca A, Gaita F, Giustetto C, Figliorneni MC, Libero L. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 1993; 39: 151-156.
247. Om A, Ellahham S, Vetrovec GW. Radiation-induced coronary artery disease. Am Heart J 1992; 124: 1.598-1.602.
248. Orzan F, Brusca A, Conte MR, Presbitero P, Figliomeni MC. Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br Heart J 1993; 69: 496-500.
249. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C et al. Cause specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-453.
250. Piovaccari G, Ferretti RM, Prati F, Traini AM, Gobbi M, Caravita L et al. Cardiac disease after chest irradiation for Hodgkin disease: incidence in 108 patients with long follow-up. Int J Cardiol 1995; 49: 39-43.
251. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL et al. Basic fibroblast growth factor protects endothelial cells aginst radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994; 54: 2.582-2.590.